Literature DB >> 15663330

Technology evaluation: Kahalalide F, PharmaMar.

Mark T Hamann1.   

Abstract

Kahalalide F is a depsipeptide under development by PharmaMar as a potential treatment for solid tumors. It is currently undergoing phase II clinical trials.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15663330      PMCID： PMC4941207     

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  18 in total

1.  A new depsipeptide from the sacoglossan mollusk Elysia ornata and the green alga Bryopsis species.

Authors:  F D Horgen; D B delos Santos; G Goetz; B Sakamoto; Y Kan; H Nagai; P J Scheuer
Journal:  J Nat Prod       Date:  2000-01       Impact factor: 4.050

2.  Kahalalides: Bioactive Peptides from a Marine Mollusk Elysia rufescens and Its Algal Diet Bryopsis sp.(1).

Authors:  Mark T. Hamann; Clifton S. Otto; Paul J. Scheuer; D. Chuck Dunbar
Journal:  J Org Chem       Date:  1996-09-20       Impact factor: 4.354

3.  Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devices.

Authors:  B Nuijen; M Bouma; C Manada; J M Jimeno; L L Lazaro; A Bult; J H Beijnen
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

4.  Synthesis and structure determination of kahalalide F (1,2).

Authors:  A López-Macià; J C Jiménez; M Royo; E Giralt; F Albericio
Journal:  J Am Chem Soc       Date:  2001-11-21       Impact factor: 15.419

5.  Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns.

Authors:  K Wosikowski; D Schuurhuis; K Johnson; K D Paull; T G Myers; J N Weinstein; S E Bates
Journal:  J Natl Cancer Inst       Date:  1997-10-15       Impact factor: 13.506

6.  Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.

Authors:  Jeany M Rademaker-Lakhai; Simon Horenblas; Willem Meinhardt; Ellen Stokvis; Theo M de Reijke; José M Jimeno; Luis Lopez-Lazaro; José A Lopez Martin; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

7.  Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells.

Authors:  Yajaira Suárez; Laura González; Ana Cuadrado; Maite Berciano; Miguel Lafarga; Alberto Muñoz
Journal:  Mol Cancer Ther       Date:  2003-09       Impact factor: 6.261

Review 8.  Progress in the clinical development of new marine-derived anticancer compounds.

Authors:  Jose Jimeno; J A López-Martín; A Ruiz-Casado; M A Izquierdo; P J Scheuer; K Rinehart
Journal:  Anticancer Drugs       Date:  2004-04       Impact factor: 2.248

9.  In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells.

Authors:  Susana G Gómez; Juan A Bueren; Glynn T Faircloth; José Jimeno; Beatriz Albella
Journal:  Exp Hematol       Date:  2003-11       Impact factor: 3.084

10.  Stereochemistry of kahalalide F.

Authors:  Isabelle Bonnard; Ignacio Manzanares; Kenneth L Rinehart
Journal:  J Nat Prod       Date:  2003-11       Impact factor: 4.050
View more
  17 in total

1.  In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.

Authors:  Abbas Gholipour Shilabin; Mark T Hamann
Journal:  Bioorg Med Chem       Date:  2011-06-25       Impact factor: 3.641

2.  Diversity-oriented synthesis of macrocyclic peptidomimetics.

Authors:  Albert Isidro-Llobet; Tiffanie Murillo; Paula Bello; Agostino Cilibrizzi; James T Hodgkinson; Warren R J D Galloway; Andreas Bender; Martin Welch; David R Spring
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-07       Impact factor: 11.205

3.  Nature's bounty - drug discovery from the sea.

Authors:  John J Bowling; Anna J Kochanowska; Noer Kasanah; Mark T Hamann
Journal:  Expert Opin Drug Discov       Date:  2007-11       Impact factor: 6.098

4.  Characterization of the bacterial community of the chemically defended Hawaiian sacoglossan Elysia rufescens.

Authors:  Jeanette Davis; W Florian Fricke; Mark T Hamann; Eduardo Esquenazi; Pieter C Dorrestein; Russell T Hill
Journal:  Appl Environ Microbiol       Date:  2013-09-06       Impact factor: 4.792

Review 5.  Chemistry and biology of kahalalides.

Authors:  Jiangtao Gao; Mark T Hamann
Journal:  Chem Rev       Date:  2011-04-11       Impact factor: 60.622

6.  Macrolactonization of peptide thioesters catalyzed by imidazole and its application in the synthesis of kahalalide B and analogues.

Authors:  Yangmei Li; Marc Giulionatti; Richard A Houghten
Journal:  Org Lett       Date:  2010-05-21       Impact factor: 6.005

7.  An efficient and cost-effective approach to kahalalide F N-terminal modifications using a nuisance algal bloom of Bryopsis pennata.

Authors:  Bin Wang; Amanda L Waters; Frederick A Valeriote; Mark T Hamann
Journal:  Biochim Biophys Acta       Date:  2015-05-09

8.  Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.

Authors:  Abbas Gholipour Shilabin; Noer Kasanah; David E Wedge; Mark T Hamann
Journal:  J Med Chem       Date:  2007-08-14       Impact factor: 7.446

9.  5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor.

Authors:  Jiangtao Gao; Catherina Caballero-George; Bin Wang; Karumanchi V Rao; Abbas Gholipour Shilabin; Mark T Hamann
Journal:  J Nat Prod       Date:  2009-12       Impact factor: 4.050

Review 10.  Production of bioactive secondary metabolites by marine vibrionaceae.

Authors:  Maria Mansson; Lone Gram; Thomas O Larsen
Journal:  Mar Drugs       Date:  2011-08-25       Impact factor: 6.085
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.